Prucalopride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Prucalopride: From Gastrointestinal Motility Disorder to Hypoalphalipoproteinemia
One-Sentence Summary
Prucalopride is a selective 5-HT4 receptor agonist known for its prokinetic effect on gastrointestinal smooth muscle, used clinically to promote bowel motility. The TxGNN model predicts it may be effective for Hypoalphalipoproteinemia (low HDL cholesterol) with a score of 99.82%, but this prediction is currently supported by 0 clinical trials and 0 publications, and the drug’s own known mechanism has no established link to lipid metabolism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in source data (drug not marketed in the EU); pharmacologically known as a GI prokinetic agent |
| Predicted New Indication | Hypoalphalipoproteinemia (low HDL cholesterol) |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in structured form (original_moa is marked as a data gap). However, the evidence pack’s own rationale identifies prucalopride as a selective 5-HT4 receptor agonist whose established pharmacology acts on gastrointestinal smooth muscle to promote motility (prokinetic effect) — consistent with its known clinical use for bowel motility disorders such as chronic constipation.
There is no known biological pathway connecting 5-HT4 receptor agonism to HDL/lipoprotein metabolism, which is the pathophysiological basis of hypoalphalipoproteinemia. The evidence pack itself explicitly states that this top-ranked prediction “likely reflects a knowledge-graph co-occurrence pattern rather than genuine biological plausibility.” In other words, the high TxGNN score is not corroborated by a credible mechanistic story, and no clinical trials or literature currently exist to support it.
Notably, several lower-ranked predictions in this same output (amyloidosis and primary amyloidosis, ranks 6 and 9) have a mechanistically coherent rationale — amyloid deposition can affect the enteric autonomic nervous system and cause GI motility impairment, which is plausibly addressable by a prokinetic agent — and are backed by preliminary literature. These may warrant separate evaluation, but they are not the top-ranked candidate covered by this report.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the SmPC for safety information.
Note: A blocking data gap exists — TFDA/EU label warnings and contraindications have not yet been retrieved, which prevents progression to the S1 safety review stage for any candidate indication of this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (hypoalphalipoproteinemia) has no clinical trial or literature support (Evidence Level L5) and lacks a credible mechanistic link to the drug’s known pharmacology. In addition, a blocking data gap in label safety information prevents any candidate from advancing to formal safety review.
To proceed, the following is needed:
- Retrieve TFDA/EU label warnings and contraindications (blocking gap, DG001)
- Confirm mechanism of action via DrugBank API (DG002)
- If pursuing repurposing further, prioritize mechanistically plausible candidates from this prediction set (e.g., amyloidosis-associated GI motility disorders) over the top TxGNN-ranked but mechanistically unsupported hypoalphalipoproteinemia indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.